Update shared on 12 Dec 2025
Fair value Increased 1.61%Analysts have modestly raised their price target on Tarsus Pharmaceuticals to approximately $88 per share from about $86, citing slightly improved fair value estimates driven by updated assumptions for long term revenue growth, profit margins, and valuation multiples.
What's in the News
- Issued new full-year 2025 revenue guidance, projecting annual revenue of $440 million to $445 million, based on company guidance about anticipated commercial performance.
Valuation Changes
- Fair Value Estimate has risen slightly, increasing from approximately $86.11 per share to about $87.50 per share.
- Discount Rate has edged down marginally, with a minor adjustment around 6.96 percent.
- Revenue Growth assumption remains effectively unchanged, holding near 38.22 percent on a long term basis.
- Net Profit Margin forecast is essentially stable, staying around 35.36 percent in the updated model.
- Future P/E multiple has risen modestly, moving from roughly 16.0 times to about 16.3 times forward earnings.
Have other thoughts on Tarsus Pharmaceuticals?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.